Cipla gets USFDA nod for generic inhaler

New Delhi: Pharma giant Cipla said that it has received final nod from the US health regulator for generic Albuterol Sulfate inhalation aerosol used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

Cipla has received final approval for its new drug application (ANDA) for Albuterol Sulfate inhalation aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (USFDA), Cipla said in a statement.

Cipla’s product is the first generic version of Merck Sharp & Dohme Corp’s Proventil HFA inhalation aerosol.

According to IQVIA (IMS Health) data, Proventil HFA inhalation aerosol and its authorised generic equivalent had US sales of about USD 153 million for the 12-month period ending February 2020, it added.

Cipla said,” The entire Albuterol Sulfate HFA inhalation aerosol market had US sales of nearly USD 2.8 billion for the 12-month period ending February 2020.”

Cipla’s MD and Global CEO Umang Vohra said, “We are pleased to receive the final approval for generic Albuterol MDI from the USFDA. This further strengthens our presence in the US market.Albuterol is the first generic metered dose inhaler of Proventil HFA inhalation aerosol ever approved by FDA in the US and Cipla’s first device-based inhalation product in the market.”

Vohra said, “This development reiterates our commitment of strengthening our respiratory franchise and will further solidify our position as lung leader globally. We will continue to build on our portfolio of drug-device combinations in the respiratory space to serve the unmet needs of our patients across markets,”

The company is also ensuring that it does its bit by donating the product in this time of need, the statement said. The product is used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

LEAVE A REPLY

Please enter your comment!
Please enter your name here